Jefferies Backs Relmada, BTIG Turns Bullish on Invivyd
Jefferies and BTIG start coverage on Relmada and Invivyd with Buy ratings, citing pipeline shifts, strong assets, and large market potential.
Jefferies and BTIG start coverage on Relmada and Invivyd with Buy ratings, citing pipeline shifts, strong assets, and large market potential.
Invivyd is developing VYD2311, a non-vaccine antibody, to prevent COVID. Two key trials (DECLARATION/LIBERTY) will test its safety and effectiveness vs. placebo and mRNA vaccines, aiming to offer a flexible new choice for protection.